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Figure 2. Overall survival among Caucasian patients compared to African
American patients during the 24-month follow-up period (Log Rank¼0.25).
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variables between the two groups were assessed using stu-
dent t-test andWilcox log rank sum test; Chi-square test was
used for categorical variables. Kaplan Meier curves were
performed to assess survival and disease progression over
time.
Results: During this time 92 AA and 317 C patients under-
went ASCT. Median follow-up was 721 days in AA (IQR,
392e1103) versus (vs.) 735 days in C (IQR, 375e1124). The
mean age of AA at time of transplant was signiﬁcantly lower
than that of Caucasian pts (55.67 8 years vs. 57.74 8 years,
p¼ .032). Durie-Salmon stage distributionwas similar in two
groups with about 60% of patients in stage III at diagnosis.
Cytogenetic risk distribution was similar in two groups: (AA
vs. C) standard risk 82% vs. 86%; intermediate risk 16% vs.
10%, p ¼ 0.17; high risk 1.5% vs. 4%, p ¼ 0.34. Disease status at
the time of transplant was CR in 8% AA vs. 21% C (p¼0.03),
VGPR in 42% AA vs. 29% C (p¼0.66) and PR in 34% AA vs. 33%
C. The median time from diagnosis to ASCT in AA was
signiﬁcantly longer than that for C {288 days; IQR
(216.75e677.50) vs. 213 days; IQR (173.50e371.50), p¼
<0.001}. Induction therapy prior to transplant consisted of
novel agent (proteasome inhibitor and/or immunomodula-
tory agent) based regimens in all patients. Median number of
cycles of induction therapy was 5 (range 4-16) vs. 4 (range 3-
22) cycles in AA vs. C. Preparative regimen for ASCT was
Melphalan 140mg/m2 in 31% vs. 26% (AA vs. C) and
Melphalan 200mg/m2 in the rest. Rate of disease progression
after two-year median follow-up was higher in the AA pts
39% vs. 27%, OR 1.75 (1.08-2.85), p ¼ 0.02 (Figure 1). There
was no difference in the overall survival in two groups
after median follow-up of two years 86% vs. 90%, OR 1.47
(0.73e2.93) p ¼ 0.27 (Figure 2).
Conclusion: AA pts are diagnosed with MM at a younger age
as compared with C population. Time from diagnosis of MM
to referral to ASCT in the AA patients is longer than in the C.
In addition, the rate of disease progression post-ASCT is
higher in AA pts.159
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Introduction: Mantle cell lymphoma (MCL) is a rare B-cell
malignancy comprising 5-10% of all non-Hodgkin lymphoma
cases. Autologous hematopoietic stem cell transplant has
emerged as a viable therapy for many patients with MCL. An
important step in the harvesting of peripheral blood he-
matopoietic stem cells (HSC) is mobilizing CD34+ HSC to the
peripheral blood. The novel compound plerixafor is an
antagonist of CXCR4, and has been successful in mobilization
of HSC for autologous stem cell transplants for non-Hodgkin
lymphoma. Increased mobilization of HSC in peripheral
blood carries the risk of increased mobilization of lymphoma
cells. Since MCL expresses CXCR4, we sought to determine
whether administration of plerixafor can adversely affect
outcome in transplantation. We report survival results of
autologous peripheral blood stem cell transplants (ASCT) for
patients with MCL who were treated with and without
plerixafor for HSC mobilization prior to ASCT at Mayo Clinic.
Methods: The present study is a retrospective cohort study
of all adult patients who underwent ASCT for treatment of
MCL at Mayo Clinic from February 1993 to December 2013.
Patients were divided into two cohorts: (1) patients treated
with plerixafor for HSC mobilization prior to ASCT, and (2)
patients not treated with plerixafor prior to ASCT. The pri-
mary outcome was relapse of MCL. Overall survival from
diagnosis and overall survival from transplant were also
analyzed.
Patients: From 1993 to 2013, 169 consecutive patients un-
derwent ASCT; 55 patients received plerixafor for HSC
mobilization prior to ASCT, and 114 patients did not receive
plerixafor. The median ages at MCL diagnosis and ASCT for
the plerixafor cohort were 57.7 years and 58.4 years,
respectively, compared with 56.6 years and 58.1 years for the
non-plerixafor cohort.
Results: The average CD34+ HSC harvest with plerixafor was
5.4  106/kg compared to 4.9  106/kg without plerixafor (p
¼ 0.13). Median progression-free survival from ASCT was 3.4
years in the plerixafor cohort compared with 3.6 years in the
non-plerixafor cohort (p ¼ 0.69). Median overall survival
from ASCT was not reached in the plerixafor cohort
compared with 5.7 years in the non-plerixafor cohort (p ¼
0.95). Median overall survival from MCL diagnosis was 8.9
years in the plerixafor cohort compared with 7.6 years in the
non-plerixafor cohort (p ¼ 0.71).
Conclusions: ASCT for treatment of MCL performed at Mayo
Clinic resulted in no statistically signiﬁcant differences in
progression-free and overall survival between patients
receiving and patients not receiving plerixafor for CD34+HSC
mobilization prior to ASCT. The results of this study indicate
that HSC mobilization using plerixafor is not associated with
decreased progression-free or overall survival from ASCT in
MCL. There appears to be no clinically signiﬁcant mobiliza-
tion of lymphoma cells associated with plerixafor mobiliza-
tion of HSC.160
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Secondary engraftment failure is deﬁned as neutrophils
increase to  0.5 x 10 ⁹/L and subsequently decrease to a
lower level until additional treatment to obtain
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female with multiple myeloma and secondary engraftment
failure after high dose chemotherapy with autologous he-
matopoietic stem cell transplantation (AHSCT) on day +64.
The patient presented with severe pancytopenia and a
bone marrow biopsy and aspirates revealed a hypocellular
marrow without increased plasma cells. An extensive in-
fectious disease work up was negative for bacterial, fungal
or viral source including cytomegalovirus, HHV 6, parovi-
rus, BK virus, and adenovirus. The patient received stem
cell boost on day +98 and failed to engraft. A repeat bone
marrow biopsy performed on day +127 revealed less than
10% cellularity with no signs of hematopoiesis and no
plasma cells. Therefore, the patient met the criteria for
severe aplastic anemia (AA). The patient was initiated on
eltrombopaq after one week treatment of steroid and
cyclosporine with minimal improvement in neutrophil
counts. Although uncommon, the case study examines the
rare occurrence of AA in the post-transplant population.
The case report highlights that secondary engraftment
failure and AA are uncommon complications of AHSCT and
can be life threatening. Careful clinical evaluation and pa-
thology review are necessary to determine the cause of
graft failure in the autologous transplant setting in order to
provide the appropriate medical and supportive care.161
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Purpose: Engraftment syndrome (ES) is a complication of
autologous hematopoietic stem cell transplantation
(HSCT) characterized by non-infectious fever, skin rash,
diarrhea, and inﬂammatory manifestations. Acute renal
dysfunction is a less frequently reported complication of
ES, occurring in up to 26% of patients. No prior investi-
gation has identiﬁed speciﬁc risk factors for developing
acute renal failure in this patient population. The objec-
tive of this study is to determine risk factors associated
with the development of acute renal dysfunction in pa-
tients with ES.
Methods: This study will be submitted to the University of
Texas Health Science Center and Veterans Affairs Institu-
tional Review Board for approval. This retrospective
cohort study will identify all patients receiving autologous
HSCT from January 2011 to December 2013 at a single
institution. Patients with a diagnosis of ES (per the
Maiolino criteria: non-infectious fever plus one of the
following: skin rash, pulmonary inﬁltrates, or diarrhea
which commences 24 hours before, or any time after
appearance of neutrophils) will be identiﬁed. Potential
risk factors that may lead to the development of acute
renal dysfunction during the time of ES will be analyzed.
Data collected will include: baseline demographics, un-
derlying malignancy, comorbid conditions, mobilization
regimen, conditioning regimen, number of CD34 cells
infused, time of engraftment, date of ﬁrst fever, physical
examination, medications, clinical lab values, and length
of hospital admission. Descriptive statistical analyses willbe performed for discrete variables by using Pearson’s chi-
squared test or Fisher’s exact test appropriately. Risk fac-
tors will be analyzed using a backward stepwise logistic
regression model.162
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Background: In 2014, high-dose chemotherapy with autol-
ogous stem cell rescue (autoSCT) was removed from the
NCCN guidelines as a recommended treatment for patients
<60 years old with intermediate-risk (int-risk) AML in ﬁrst
complete remission (CR1). We comprehensively reviewed
the long-term outcomes of all patients with int-risk AML
treated with autoSCT in CR1 at our institution.
Patients and Methods: This is a retrospective, single insti-
tution study of all patients with int-risk AML treated with
autoSCT in CR1 between 1988-2013. Data were collected by
chart review. Publicly available death indices were accessed
to ensure accurate dates of death, with censoring of data on
September 1, 2014. For all analyses, patients with <1 year
follow-up were considered to have relapsed at the date of
last follow-up. Statistical analyses were performed using
STATA SE 9.
Results: We identiﬁed 133 patients with int-risk AML who
underwent autoSCT in CR1. Cytogenetics were diploid in 97
(73%); FLT3mutation status was only assessed routinely after
2008 (21 patients total, 17/21 negative).
Of the 133 patients, 55% were women and 69% were
Caucasian. Median age at autoSCT was 47 years (range 20-
72). Mean CD34+ cell dose infused was 13 x 106/kg (range
2.6-63). Ten percent of patients were treated pre-1993 with
bone marrow stem cells and PO busulfan (BU), 28% between
1993-2003 with peripheral blood stem cells (PBSCs) and PO
BU, 35% between 2003-2007 with PBSCs and IV BU, and 28%
post-2007 with PBSCs and targeted IV BU (all with 60mg/kg
IV etoposide).
With a median follow-up of 4.3 years (range 0.1-17),
median relapse-free survival (RFS) has not been reached; 52%
of patients remain relapse-free. Fourteen (10%) patients
developed therapy-related MDS or AML. In multivariate
analysis, relapse was predicted by non-Caucasian race (HR
2.5, p¼0.001) and by treatment era post-2007 (HR 1.85,
p¼0.025). Median overall survival (OS) for the entire cohort
is 6.6 years (range 0.1-17).
Twenty-six of 54 relapsing patients (48%) subsequently
received an alloSCT, with 16 (62%) proceeding to alloSCT in
CR2 and 7 (27%) with active disease. Twelve (46%) patients
relapsed following alloSCT. Of the 26 alloSCT patients, 9
(35%) died from treatment-related causes and 9 (35%) from
AML relapse. Median follow-up for patients receiving salvage
alloSCT is 3.8 years (range 0.17-7.8) with 8 (31%) patients
known to be alive and in remission. Median RFS after alloSCT
is 2.5 years (range 0.02-4.32).
